On Sept. 3, 2020, Humanigen announced the first case-control data of lenzilumab in severe COVID-19 demonstrated an 80% reduction in relative risk of invasive mechanical ventilation and/or death for patients treated with lenzilumab compared to the matched control group.

Lenzilumab, the company’s proprietary Humaneered anti-human granulocyte macrophage-colony stimulating factor monoclonal antibody drug candidate, was evaluated in an ongoing Phase III trial and was selected by the National Institutes of Health (NIH) for its COVID-19 Big Effect Trial. The manuscript was published in Mayo Clinic Proceedings, a premier peer-reviewed journal.